Chelsea Therapeutics International 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2012
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On March 28, 2012, Chelsea Therapeutics International, Ltd. issued a press release announcing that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application (NDA) for NORTHERA (droxidopa) Capsules for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy. The Company will host a conference call on Thursday, March 29, 2012 at 8:00 a.m. Eastern Time and interested investors may participate in the conference call by dialing (877) 638-9567 (domestic) or (720) 545-0009 (international) and Conference ID: 66986297. Access to the live webcast will be available via the InvestorsEvents & Presentations section of the Companys website at www.chelseatherapeutics.com. A replay will also be available for one week following the conference call.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.